StreetInsider.com News Articles

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0400

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0400

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0400

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0400

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Quest Diagnostics (DGX) PT Raised to $250 at UBS

Mon, 19 Oct 2026 09:12:17 -0400

UBS analyst Kevin Caliendo raised the price target on Quest Diagnostics (NYSE: DGX) to $250.00 (from $245.00) while maintaining a Neutral rating.

Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension

Mon, 19 Oct 2026 07:57:00 -0400

Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds

SECAUCUS, N.J., Oct. 19, 2026 /PRNewswire/ -- A new study finds that current medical guidelines may inadvertently lead to under-diagnosis of primary aldosteronism (PA), a hormonal disorder associated with hypertension that can significantly raise a person's risk of heart attack, stroke and kidney

Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension

Mon, 19 Oct 2026 07:57:00 -0400

Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds

Quest Diagnostics (DGX) PT Raised to $260 at Barclays

Wed, 07 Oct 2026 03:51:37 -0400

Barclays analyst Luke Sergott raised the price target on Quest Diagnostics (NYSE: DGX) to $260.00 (from $250.00) while maintaining a Overweight rating.

Form 8-K QUEST DIAGNOSTICS INC For: Oct 06

Tue, 06 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261006/27155951.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 01 Filed by: WENTWORTH TIMOTHY C

Fri, 02 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261002/27142918.html

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

Thu, 01 Oct 2026 08:52:00 -0400

Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence

SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

Thu, 01 Oct 2026 08:52:00 -0400

Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence

SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

Tue, 22 Sep 2026 16:28:00 -0400

SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

Tue, 22 Sep 2026 16:28:00 -0400

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

The analyst comments "After the close yesterday, the Centers for Medicare and Medicaid Services (CMS) released preliminary Calendar Year (CY) 2027 Clinical Laboratory Fee Schedule (CLFS) payment rates under the Protecting Access to Medicare Act (PAMA), the first repricing since 2018. The average potential change to CY2026 rates is ~16% lower. Cuts are broadly concentrated in esoteric testing while Proprietary Laboratory Analysis is relatively insulated at -2.4%. Final rates are expected to be released in November. We would note that LH's adjusted EPS CAGR of +8.5%-11.5% provided at the 2026 Investor

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

Quest Diagnostics (DGX) PT Raised to $260 at Baird

Tue, 22 Sep 2026 07:23:43 -0400

Baird analyst Eric Coldwell raised the price target on Quest Diagnostics (NYSE: DGX) to $260.00 (from $255.00) while maintaining a Neutral rating.

Evercore comments on LH and DGX post CMS on Monday

Tue, 22 Sep 2026 06:29:53 -0400

Evercore comments on LH and DGX post CMS on Monday.

The analyst comments "What Happened? CMS released preliminary CY2027 CLFS rates today, based on the second PAMA private-payor rate survey. Based on the survey, CMS’s preliminary numbers note that Medicare has been paying ~16% more than private payors for lab services. PAMA has a maximum price cut of 15% on any single code's cut, which is to start January 1, 2027 and be phased in through 2029. These are preliminary rates and we now enter into a 30-day of comment period before final rates are expected in November. Our Take: Today’s

Evercore comments on LH and DGX post CMS on Monday

Tue, 22 Sep 2026 06:29:53 -0400

Evercore comments on LH and DGX post CMS on Monday.

Evercore comments on LH and DGX post CMS on Monday

Tue, 22 Sep 2026 06:29:53 -0400

Evercore comments on LH and DGX post CMS on Monday.

Evercore comments on LH and DGX post CMS on Monday

Tue, 22 Sep 2026 06:29:53 -0400

Evercore comments on LH and DGX post CMS on Monday.

CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk

Mon, 21 Sep 2026 16:35:25 -0400

Investing.com - Medicare has been overpaying laboratories by roughly 16% compared with private insurers, the Centers for Medicare & Medicaid Services disclosed Monday, and it intends to close that gap through annual reimbursement cuts of up to 15% beginning January 1, 2027.

CMS released preliminary Calendar Year 2027 Clinical Laboratory Fee Schedule rates on September 21, 2026, estimating the realignment will save taxpayers approximately $1 billion annually, according to the agency's press release. Quest Diagnostics (NYSE: DGX) and Labcorp (NYSE: LH), which both derive a substantial portion of revenue from routine clinical testing reimbursed directly under the CLFS, are the most

CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk

Mon, 21 Sep 2026 16:35:25 -0400